TERN - NASDAQ

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

TERNยทNASDAQ

$52.95

+0.0000%
HealthcareBiotechnology

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$4.77B
EPS-1.0300
P/E Ratio-51.41
Earnings Date05/14/2026
Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Fair Value Envelope

TERN ยท NASDAQ

Our analysis suggests that TERN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $52.95, this represents a potential HIDDEN relative to our calculated worth for Terns Pharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $52.95

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$250.0M
+ Cash & Equivalents$524.7M
Firm Value$274.7M
- Debt$919.0K
Equity Value$273.8M
/ Shares Outstanding90,077,698B
DCF Value$3
OVERVALUED BY 94%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$68.0M
-$56.2M
-$46.5M
-$38.4M
-$31.8M
-$26.3M
-$21.7M
-$18.0M
-$14.9M
-$12.3M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$68.0M
-$56.2M
-$46.5M
-$38.4M
-$31.8M
-$26.3M
-$21.7M
-$18.0M
-$14.9M
-$12.3M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$62.9M
-$48.2M
-$36.9M
-$28.3M
-$21.6M
-$16.6M
-$12.7M
-$9.7M
-$7.4M
-$5.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TERN research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.